Overview
Balance Sheet
Cash Flow
Growth Analysis
2023
2023
2022
2022
2021
Profitability Metrics
Gross Margin
40.74%
Operating Margin
5.65%
Net Margin
0.44%
Efficiency Metrics
Revenue per Expense Ratio
1.06
R&D as % of Revenue
0.00%
Earnings Quality
EBITDA Margin
9.41%
Income Tax Rate
15.32%
EPS
0.3800000000
Balance Sheet Analysis
Current Ratio
1.37
Cash Ratio
0.23
Working Capital
$1.66B
Debt to Equity
1.45
Debt to Assets
36.83%
Equity Ratio
25.46%
Cash Flow Analysis
Operating Cash Flow Ratio
5.47%
Free Cash Flow Ratio
1.31%
CapEx to Revenue
4.16%
Dividends Paid
$181.00M
Stock Buybacks
$38.00M
Total Shareholder Returns
$219.00M
Cash Position Change
19.95%
Key Takeaways (2023 FY)
Revenue declined by 5.6866231969966%, indicating potential market challenges
Increased dividend payments by 4.82%
Detailed Growth Metrics
Core Performance
Revenue
-5.69%
Net Income
-91.08%
EPS
-91.12%
Operating Income
-77.92%
Operational Efficiency
R&D Expenses
0.00%
SG&A Expenses
2.31%
Operating Cash Flow
-19.20%
Free Cash Flow
-2.50%
Balance Sheet Health
Assets
-3.68%
Debt
-0.86%
Book Value per Share
1.53%
Inventory
2.20%
Shareholder Returns
Dividends per Share
4.82%
Shares Outstanding
-0.18%
Long Term Trends
3Y Revenue/Share
49.63%
5Y Revenue/Share
4.05%
3Y Dividend/Share
75.52%
5Y Dividend/Share
-56.13%